Holen Sie sich die Stockscreener-App
6.82
0.29%
-0.02
Handel nachbörslich:
6.74
-0.08
-1.17%
Schlusskurs vom Vortag:
$6.84
Offen:
$6.93
24-Stunden-Volumen:
97,306
Relative Volume:
0.42
Marktkapitalisierung:
$94.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-56.20M
KGV:
-1.9104
EPS:
-3.57
Netto-Cashflow:
$-39.97M
1W Leistung:
-10.85%
1M Leistung:
-25.95%
6M Leistung:
-17.93%
1J Leistung:
+12.36%
1-Tages-Spanne:
$6.71
$6.97
1-Wochen-Bereich:
$6.68
$7.80
52-Wochen-Spanne:
$4.53
$22.49
Annovis Bio Inc Stock (ANVS) Company Profile
Firmenname
Annovis Bio Inc
Sektor
Branche
Telefon
484-875-3192
Adresse
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Vergleichen Sie ANVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| ANVS | 6.82 | 94.93M | 0 | -56.20M | -39.97M | -3.57 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-07-07 | Bestätigt | Maxim Group | Buy |
Annovis Bio Inc Aktie (ANVS) Neueste Nachrichten
Annovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial Updates - MSN
When the Price of (ANVS) Talks, People Listen - Stock Traders Daily
Annovis Bio (NYSE: ANVS) Concludes Q3 with Milestones, FDA-Cleared Phase 3 Program for Alzheimer’s - Barchart
Annovis Bio Inc (ANVS-N) QuotePress Release - The Globe and Mail
Q4 Earnings Forecast for Annovis Bio Issued By HC Wainwright - MarketBeat
Annovis Bio Welcomes New Senior Clinical Scientist to Lead Key Studies - MSN
Annovis Bio (NYSE: ANVS) CEO To Showcase Buntanetap’s Dual Benefits At NIA Workshop - Barchart
Veravas and Phanes Biotech Collaborate to Innovate Alzheimer’s Disease Testing - MyChesCo
Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB) - GlobeNewswire
Annovis Bio CEO to Present Breakthrough Drug Research at NIA Dementia Workshop | ANVS Stock News - StockTitan
Annovis Bio (NYSE: ANVS) Advances Alzheimer’s Phase 3 Trials with Strong FDA Support, Financial Backing - Barchart
Annovis Bio (NYSE:ANVS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Annovis Bio Reports Third Quarter Financial Results and Provides Business Update - The Manila Times
Annovis sees cash runway for Phase 3 preparatory studies, entering AD study - Nasdaq
Annovis Bio Gets FDA Nod for Phase 3 Alzheimer's Trial, Cuts Losses 40% in Q3 | ANVS Stock News - StockTitan
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Will Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely? - Yahoo Finance
Annovis Bio Inc (ANVS) Quarterly 10-Q Report - Quartzy
Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist - citybiz
Annovis Bio (NYSE: ANVS) Highlights Buntanetap Results at 17th Clinical Trials on Alzheimer’s Disease Conference - Barchart
(ANVS) Technical Pivots with Risk Controls - Stock Traders Daily
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio - GlobeNewswire
Annovis Bio (NYSE: ANVS) Moving Closer to Providing Much-Needed Treatments to Patients - Barchart
Brokerages Set Annovis Bio, Inc. (NYSE:ANVS) PT at $32.17 - MarketBeat
Annovis Bio (NYSE:ANVS) Raised to Buy at Maxim Group - MarketBeat
Annovis Bio to Present Key Alzheimer’s Research at CTAD Conference - MSN
Annovis Bio (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s Studies - Barchart
Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024 - The Manila Times
Annovis Bio files three drug patents - Pennsylvania Business Report
Annovis Bio: Funding May Be An Issue For Announced Phase 3 Trials (NYSE:ANVS) - Seeking Alpha
Annovis Bio To Continue Alzheimer's Disease Clinical Trials (NYSE:ANVS) - Seeking Alpha
Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug - Yahoo Finance
Annovis Bio shares hold Buy rating from HC Wainwright - Investing.com India
Annovis Bio Stock Surges As Analyst Reiterates ‘Buy’ On Alzheimer’s Drug Progress: Retail Stays Bullish - Barchart
Annovis Bio shares hold Buy rating from HC Wainwright By Investing.com - Investing.com UK
In the Green: Annovis Bio Inc (ANVS) Closes at 7.98, Up/Down 6.26 from Previous Day - The Dwinnex
Annovis Bio (NYSE:ANVS) Given Buy Rating at HC Wainwright - MarketBeat
(ANVS) Investment Analysis and Advice - Stock Traders Daily
Annovis Bio Advances Alzheimer’s Treatment with FDA Approval for Phase 3 Trials - MyChesCo
Annovis Bio (ANVS) Stock Soars After FDA Approval - Stocks Telegraph
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs - The Manila Times
FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs - GlobeNewswire
Freedom Village Hosts Successful Third Annual Walk to End Alzheimer’s - MyChesCo
(ANVS) On The My Stocks Page - Stock Traders Daily
Finanzdaten der Annovis Bio Inc-Aktie (ANVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):